AU2009334869A1 - Substituted quinazoline compounds - Google Patents

Substituted quinazoline compounds Download PDF

Info

Publication number
AU2009334869A1
AU2009334869A1 AU2009334869A AU2009334869A AU2009334869A1 AU 2009334869 A1 AU2009334869 A1 AU 2009334869A1 AU 2009334869 A AU2009334869 A AU 2009334869A AU 2009334869 A AU2009334869 A AU 2009334869A AU 2009334869 A1 AU2009334869 A1 AU 2009334869A1
Authority
AU
Australia
Prior art keywords
phenyl
quinazolin
compound
chloro
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009334869A
Other languages
English (en)
Other versions
AU2009334869A2 (en
Inventor
Eric Auclair
Jacques Le Roux
Caroline Leriche
David N. Middlemiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fovea Pharmaceuticals SA
Original Assignee
Fovea Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41735344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009334869(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals SA filed Critical Fovea Pharmaceuticals SA
Publication of AU2009334869A1 publication Critical patent/AU2009334869A1/en
Publication of AU2009334869A2 publication Critical patent/AU2009334869A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2009334869A 2008-12-29 2009-12-18 Substituted quinazoline compounds Abandoned AU2009334869A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08360043.7 2008-12-29
EP08360043 2008-12-29
PCT/EP2009/067494 WO2010076238A1 (en) 2008-12-29 2009-12-18 Substituted quinazoline compounds

Publications (2)

Publication Number Publication Date
AU2009334869A1 true AU2009334869A1 (en) 2011-07-14
AU2009334869A2 AU2009334869A2 (en) 2011-09-29

Family

ID=41735344

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009334869A Abandoned AU2009334869A1 (en) 2008-12-29 2009-12-18 Substituted quinazoline compounds

Country Status (23)

Country Link
US (1) US8389530B2 (cg-RX-API-DMAC7.html)
EP (1) EP2381943A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012514020A (cg-RX-API-DMAC7.html)
KR (1) KR20110120878A (cg-RX-API-DMAC7.html)
CN (1) CN102333533A (cg-RX-API-DMAC7.html)
AU (1) AU2009334869A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0924067A2 (cg-RX-API-DMAC7.html)
CA (1) CA2748319A1 (cg-RX-API-DMAC7.html)
CO (1) CO6390105A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110368A (cg-RX-API-DMAC7.html)
DO (1) DOP2011000209A (cg-RX-API-DMAC7.html)
EA (1) EA019110B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011204A (cg-RX-API-DMAC7.html)
IL (1) IL213742A0 (cg-RX-API-DMAC7.html)
MA (1) MA32968B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011007064A (cg-RX-API-DMAC7.html)
NI (1) NI201100134A (cg-RX-API-DMAC7.html)
NZ (1) NZ593949A (cg-RX-API-DMAC7.html)
PE (1) PE20120424A1 (cg-RX-API-DMAC7.html)
SG (1) SG172415A1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000319A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010076238A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201104777B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
KR101715448B1 (ko) * 2014-07-16 2017-03-20 주식회사 큐리언트 염증성 질환 치료용 화합물
CA2972014C (en) 2014-12-24 2019-09-24 Gilead Sciences, Inc. Fused pyrimidine compounds for the treatment of hiv
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
SG11201705184PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Isoquinoline compounds for the treatment of hiv
CN112239459B (zh) * 2019-07-19 2021-11-26 中国科学院上海药物研究所 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用
CN115916759B (zh) * 2020-06-19 2025-07-15 泰州红云制药有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386955A1 (en) * 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
WO2005037285A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
NZ588896A (en) 2004-08-25 2012-05-25 Targegen Inc Heterocyclic compounds and methods of use
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006101977A2 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
EP1878727A4 (en) * 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
WO2006133411A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
CA2673003A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition

Also Published As

Publication number Publication date
EA201101012A1 (ru) 2012-01-30
NZ593949A (en) 2013-08-30
TN2011000319A1 (en) 2012-12-17
SG172415A1 (en) 2011-07-28
US8389530B2 (en) 2013-03-05
MA32968B1 (fr) 2012-01-02
CO6390105A2 (es) 2012-02-29
CN102333533A (zh) 2012-01-25
ECSP11011204A (es) 2011-10-31
CR20110368A (es) 2011-12-02
BRPI0924067A2 (pt) 2016-01-26
ZA201104777B (en) 2012-03-28
MX2011007064A (es) 2012-01-20
IL213742A0 (en) 2011-07-31
NI201100134A (es) 2012-03-06
DOP2011000209A (es) 2011-09-30
PE20120424A1 (es) 2012-05-04
WO2010076238A1 (en) 2010-07-08
KR20110120878A (ko) 2011-11-04
AU2009334869A2 (en) 2011-09-29
US20120004210A1 (en) 2012-01-05
EA019110B1 (ru) 2014-01-30
EP2381943A1 (en) 2011-11-02
CA2748319A1 (en) 2010-07-08
JP2012514020A (ja) 2012-06-21

Similar Documents

Publication Publication Date Title
US8389530B2 (en) Substituted quinazoline compounds
US20120041195A1 (en) Heterocyclic compounds
TWI235752B (en) Inhibitors of c-JUN N-terminal kinases (JNK) and other protein kinases
KR101812390B1 (ko) 키나제 억제제로서의 치환된 트리시클릭 벤즈이미다졸
JP4440642B2 (ja) ピリミジンA2b選択的アンタゴニスト化合物、それらの合成、及び使用
AU2006224605B2 (en) Potassium channel modulating agents and their medical use
US20130123271A1 (en) Heterocyclic compounds, their preparation and therapeutic application
JP2002541109A (ja) ソルビトールデヒドロゲナーゼ阻害薬としてのアミノピリミジン
SG177289A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
JP2010522186A (ja) 化合物
KR20020027347A (ko) 5-시아노-2-아미노피리미딘 유도체들
EP1863796A1 (en) Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use
US20090036475A1 (en) Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
ES2207497T3 (es) 1,4-dihidroindeno(1,2-c)pirazoles sustituidos como inhibidores de tirosina quinasa.
AU2011211410B2 (en) [1,2,4] triazolo [1,5-A] pyridines as kinase inhibitors
OA16290A (en) Heterocyclic compounds, their preparation and their therapeutic application.

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 SEP 2011

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 OCT 2011

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period